Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2025)

Rani Therapeutics Holdings has reported Net Cash Flow over the past 6 years, most recently at $14.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $14.2 million for Q4 2025, up 2854.95% from a year ago — trailing twelve months through Dec 2025 was $14.6 million (up 793.15% YoY), and the annual figure for FY2025 was $14.6 million, up 793.15%.
  • Net Cash Flow for Q4 2025 was $14.2 million at Rani Therapeutics Holdings, up from -$6.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for RANI hit a ceiling of $60.4 million in Q3 2021 and a floor of -$69.5 million in Q3 2022.
  • Median Net Cash Flow over the past 5 years was -$1.4 million (2024), compared with a mean of -$2.7 million.
  • Peak annual rise in Net Cash Flow hit 2854.95% in 2025, while the deepest fall reached 2462.03% in 2025.
  • Rani Therapeutics Holdings' Net Cash Flow stood at -$12.3 million in 2021, then skyrocketed by 98.28% to -$212000.0 in 2022, then skyrocketed by 520.75% to $892000.0 in 2023, then plummeted by 157.74% to -$515000.0 in 2024, then soared by 2854.95% to $14.2 million in 2025.
  • The last three reported values for Net Cash Flow were $14.2 million (Q4 2025), -$6.1 million (Q3 2025), and $105000.0 (Q2 2025) per Business Quant data.